BioCentury | Nov 25, 2020
Product Development

Nov. 25 Quick Takes: FDA approves Y-mAbs’ Danyelza; plus NIH’s ACTT-4; COVAXX, Urovant, SomaLogic, Eluminex and Liquidia

...is an adjunct professor of vascular and interventional radiology at Stanford University and was CMO at Graybug...
BioCentury | Oct 16, 2020
Deals

Fresh off Everest’s Hong Kong debut, CBC planning IPO for newly merged portfolio companies

...for wet AMD. AffaMed gained the right of first negotiation and refusal to GB-102 in July 2019 from Graybug...
...licensed the Parkinson’s therapy from Kissei Pharmaceutical Co. Ltd. (Tokyo:4547) earlier this month. AffaMed’s agreement with Graybug...
BioCentury | Sep 26, 2020
Finance

Data Bytes: oncology pair shines in NASDAQ debut as queue swells

...each posted double-digit gains in their first trading day on NASDAQ Friday, while ophthalmic play Graybug...
...its valuation to $1.1 billion. That biotech has two clinical programs targeting PRMT5.The lead program of Graybug...
...offering price by Friday’s close.  TARGETSPRMT5 – Protein arginine methyltransferase 5 Paul Bonanos Prelude Therapeutics Inc. PMV Pharmaceuticals Inc. Graybug...
BioCentury | Sep 8, 2020
Management Tracks

Black Diamond names Humphrey CMO; plus Edmondson to lead chemistry at Nimbus, Recce, Amarna and more

...the RWE client partner sales team for the Americas and Europe at Kantar Health.Ophthalmology play Graybug...
BioCentury | May 20, 2020
Management Tracks

Former Allergan execs join Merck spinout; plus Ping An ousts Tao, and updates from Mirati, Evox, Ardelyx, Akcea, Horama and more

...served as CSO of Yumanity Therapeutics LLC (see “More Waves to Come” ). Ophthalmology company Graybug...
...Healthcare and Technology Co. Ltd. Mirati Therapeutics Inc. Evox Therapeutics Ardelyx Inc. Akcea Therapeutics Inc. Horama S.A. Cellectis S.A. Wave Life Sciences Ltd. GrayBug Inc....
BioCentury | Aug 21, 2019
Financial News

Aug. 20 Financial Quick Takes: WuXi companies report increased profits; plus Graybug, Araris and Sarepta

...at its manufacturing sites. Graybug raises $80 million series C, Michael Keyoung to join board Graybug...
...Phase IIa study in macular edema secondary to diabetic macular edema or retinal vein occlusion. Graybug...
..."Sarepta Sinks After FDA Rejects DMD Therapy" ). Mary Romeo, Assistant Editor and Hongjiang Li, Staff Writer Graybug...
BioCentury | Feb 8, 2019
Company News

Management tracks: Takeda’s Plump becomes president of R&D

...ulcerative colitis, and SER-109, which is in Phase III testing for recurrent Clostridium difficile infection. Graybug...
...gene therapy targeting caveolin 1 caveolae protein 22kDa (CAV1) overexpression to treat neurodegenerative diseases. BC Staff CaroGen Corp. Graybug...
BioCentury | Jun 9, 2017
Company News

Management tracks

...services and CSO at Dohmen Life Science Services Inc. (Milwaukee, Wis.); Templeman was COO at Graybug...
BioCentury | Jan 3, 2017
Company News

Management tracks

...development and companion diagnostics at the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY). Opthalmology company Graybug...
BioCentury | Jun 22, 2016
Company News

Management tracks

...was SVP of development and CMO at Alvine Pharmaceuticals Inc. (San Carlos, Calif.). Ophthalmic company Graybug...
Items per page:
1 - 10 of 18
BioCentury | Nov 25, 2020
Product Development

Nov. 25 Quick Takes: FDA approves Y-mAbs’ Danyelza; plus NIH’s ACTT-4; COVAXX, Urovant, SomaLogic, Eluminex and Liquidia

...is an adjunct professor of vascular and interventional radiology at Stanford University and was CMO at Graybug...
BioCentury | Oct 16, 2020
Deals

Fresh off Everest’s Hong Kong debut, CBC planning IPO for newly merged portfolio companies

...for wet AMD. AffaMed gained the right of first negotiation and refusal to GB-102 in July 2019 from Graybug...
...licensed the Parkinson’s therapy from Kissei Pharmaceutical Co. Ltd. (Tokyo:4547) earlier this month. AffaMed’s agreement with Graybug...
BioCentury | Sep 26, 2020
Finance

Data Bytes: oncology pair shines in NASDAQ debut as queue swells

...each posted double-digit gains in their first trading day on NASDAQ Friday, while ophthalmic play Graybug...
...its valuation to $1.1 billion. That biotech has two clinical programs targeting PRMT5.The lead program of Graybug...
...offering price by Friday’s close.  TARGETSPRMT5 – Protein arginine methyltransferase 5 Paul Bonanos Prelude Therapeutics Inc. PMV Pharmaceuticals Inc. Graybug...
BioCentury | Sep 8, 2020
Management Tracks

Black Diamond names Humphrey CMO; plus Edmondson to lead chemistry at Nimbus, Recce, Amarna and more

...the RWE client partner sales team for the Americas and Europe at Kantar Health.Ophthalmology play Graybug...
BioCentury | May 20, 2020
Management Tracks

Former Allergan execs join Merck spinout; plus Ping An ousts Tao, and updates from Mirati, Evox, Ardelyx, Akcea, Horama and more

...served as CSO of Yumanity Therapeutics LLC (see “More Waves to Come” ). Ophthalmology company Graybug...
...Healthcare and Technology Co. Ltd. Mirati Therapeutics Inc. Evox Therapeutics Ardelyx Inc. Akcea Therapeutics Inc. Horama S.A. Cellectis S.A. Wave Life Sciences Ltd. GrayBug Inc....
BioCentury | Aug 21, 2019
Financial News

Aug. 20 Financial Quick Takes: WuXi companies report increased profits; plus Graybug, Araris and Sarepta

...at its manufacturing sites. Graybug raises $80 million series C, Michael Keyoung to join board Graybug...
...Phase IIa study in macular edema secondary to diabetic macular edema or retinal vein occlusion. Graybug...
..."Sarepta Sinks After FDA Rejects DMD Therapy" ). Mary Romeo, Assistant Editor and Hongjiang Li, Staff Writer Graybug...
BioCentury | Feb 8, 2019
Company News

Management tracks: Takeda’s Plump becomes president of R&D

...ulcerative colitis, and SER-109, which is in Phase III testing for recurrent Clostridium difficile infection. Graybug...
...gene therapy targeting caveolin 1 caveolae protein 22kDa (CAV1) overexpression to treat neurodegenerative diseases. BC Staff CaroGen Corp. Graybug...
BioCentury | Jun 9, 2017
Company News

Management tracks

...services and CSO at Dohmen Life Science Services Inc. (Milwaukee, Wis.); Templeman was COO at Graybug...
BioCentury | Jan 3, 2017
Company News

Management tracks

...development and companion diagnostics at the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY). Opthalmology company Graybug...
BioCentury | Jun 22, 2016
Company News

Management tracks

...was SVP of development and CMO at Alvine Pharmaceuticals Inc. (San Carlos, Calif.). Ophthalmic company Graybug...
Items per page:
1 - 10 of 18